Search

everythinglearnresearchcommunity

for

Search:↓

User shares link to conference about Pyrilutamide. Discussion includes phase 2 results, company's plans, and upcoming phase 3 trial.

Hair loss discussion includes treatments Min, Fin, and RU. Kintor's KX-826 Phase 2 data release delayed to September due to COVID.

The user reviewed the Kiierr 312 MD DualWave Laser for hair loss, using it alongside ketoconazole shampoo, Svvimer products, and oral finasteride. They also mentioned using minoxidil on their face and adjusting lifestyle factors like sleep, vitamin D, and protein intake.

Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.

KOSHINE826 is a new anti-hair loss and hair growth solution that claims to effectively control oil, reduce hair fall, and promote real hair growth. It targets androgenetic alopecia by inhibiting DHT and has shown promising results in clinical trials.

Breezula (cb-03-01) and kx-826 are discussed as hair loss treatments. Kx-826 is available on Kintor's website, while Breezula is available on the grey market.

OP developed hives after using Kx 826 (Pyrilutamide) 1% twice daily for 3 weeks. The hives appeared on the arms, chest, and groin area.

The conversation is about seeking information on GT20029 from Kintor Pharmaceutical as a potential hair loss cure and inquiring about experiences with CosmeaRNA.

The conversation is about purchasing KX-826 (Pyrilutamide) on Amazon, now called Koshine. A user mentioned their order is expected to arrive between August 22 and September 13.

First patient dosed with Pyrilutamide (Kintor) Phase III for hair loss treatment. Pyrilutamide differs from approved treatments as it competes with DHT to bind hair follicles, potentially reducing side effects.

The conversation discusses organizing group buys and tracking progress for Kx-826 Pyrilutamide, a hair loss treatment. Participants express optimism about upcoming results and concerns about self-reporting bias.

Kintor's Pyrilutamide results for hair loss treatment will be released soon. The treatment may replace current treatments like finasteride and minoxidil without systemic side effects.

KX-826 may cause increased hair loss for some users, leading to concerns about its effects. One user reported no issues but also no hair regrowth, only maintenance.

SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.

KX-826 users report increased shedding, with some experiencing more shedding at higher concentrations. Users are discussing where to purchase the product.

KX-826 hair loss treatment completed trials with mild side effects. GT20029 may be ultimate cure, destroying androgen receptors causing baldness.

The conversation discusses the less impressive results of Pyrilutamide (kx-836) in phase 3 compared to phase 2, with a suggestion that a longer study might show more significant results. One user reports personal success with Pyrilutamide, experiencing no further hair loss and gradual regrowth.

Kintor KX-826, a hair loss treatment, is being discussed for its pricing and effectiveness, with a focus on whether the 0.9% concentration is more effective than the 0.5%. Users are seeking cheaper purchasing options.

The conversation is about starting a Discord group for people using KX-826 as their only treatment for hair loss, excluding those who are not serious or use multiple treatments. Someone agrees with the idea but mentions "GP :3," which is unclear.

Kintor Pharmaceutical's KX-826 shows promising results for hair loss treatment. Users discuss the use of anti-androgens like spironolactone and RU58841, noting concerns about concentration and safety.

A user shared their six-month hair regrowth journey using Kirkland minoxidil, micro-needling, keto shampoo, and hims topical spray with minoxidil and finasteride. They reported noticeable hair improvement with minimal side effects and plan to continue the routine.

The conversation discusses concerns about importing Koshine KX, a hair loss treatment. A user reassures that there is no risk of getting caught.

Kintor's KX826 (pyrilutamide) is ineffective at 0.5% and overpriced at 1%, leading to user frustration and calls for fair pricing. Users suggest sticking with proven treatments like Minoxidil and Finasteride.

KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.

A user shared their 6-month hair loss treatment journey using minoxidil, finasteride, ketoconazole, and a dermaroller, noting minimal changes between months 3 and 6. Other users discussed similar routines, cutting finasteride pills, and the benefits of using a dermastamp over a roller.

The user is 2 months post-hair transplant with 6,000 grafts using the DHI method and is using oral finasteride, minoxidil, and vitamins. They are seeking feedback on their progress.

A user's 6-month progress with treating their hair loss using finasteride, minoxidil, and Nizoral shampoo.

The user is experiencing shedding of thick, healthy hair after using KX826 0.5% for a month. They are concerned about losing coverage and are seeking others' experiences with regrowth.

Kintor Pyrilutamide treatment, a potential hair loss treatment that may become available to the public soon. People have been experimenting with using it in topical form, with mixed results and no reported side effects.

People are discussing their experiences with kx-826 (pyrilutamide) for hair loss, using concentrations of 0.5% and 0.9%. They are sharing personal results and progress with this treatment.